University of Geneva Licenses Chromatin Binding Technology to GeneSoft | GenomeWeb

NEW YORK, April 11 – The University of Geneva has licensed a key DNA-binding technology to Gene Soft, a South San Francisco, Calif.-based biotechnology company that is developing small molecule DNA sequence specific drugs, the organizations said Wednesday.

This technology, developed by Ulrich Laemmi, a professor of molecular biology at the University of Geneva, involves DNA-binding molecules that act to change the structure of chromatin, the complex formed by DNA and the proteins to make chromosomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.